Granisetron

Chemical formula: C₁₈H₂₄N₄O  Molecular mass: 312.417 g/mol  PubChem compound: 5284566

Therapeutic indications

Granisetron is indicated for:

Nausea and vomiting associated with chemotherapy and radiotherapy

Population group: only adults (18 years old or older)

Granisetron is indicated in adults for the treatment of acute nausea and vomiting associated with chemotherapy and radiotherapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Prevention of nausea and vomiting associated with chemotherapy and radiotherapy

Population group: only adults (18 years old or older)

Granisetron is indicated in adults for the prevention of acute nausea and vomiting associated with chemotherapy and radiotherapy.

Granisetron is indicated in adults for prevention of delayed nausea and vomiting associated with chemotherapy and radiotherapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Nausea and vomiting associated with chemotherapy and radiotherapy

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Granisetron is indicated in children aged 2 years and above for the treatment of acute nausea and vomiting associated with chemotherapy and radiotherapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Prevention of nausea and vomiting associated with chemotherapy and radiotherapy

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Granisetron is indicated in children aged 2 years and above for the prevention of acute nausea and vomiting associated with chemotherapy and radiotherapy.

Granisetron is indicated in children aged 2 years and above for prevention of delayed nausea and vomiting associated with chemotherapy and radiotherapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Post-operative nausea and vomiting (PONV)

Population group: only adults (18 years old or older)

at least one of
Postoperative nausea and vomiting
Postoperative nausea
Postoperative vomiting

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2019: SANCUSO Transdermal patch
Summary of Product Characteristics (SPC) 2018: GRANISETRON Film-coated tablet
Summary of Product Characteristics (SPC) 2019: GRANISETRON Concentrate for solution for injection or infusion
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈